Regeneron loses opposition to Kymab’s patent for human rats
Ben Fitzpatrick 2019-08-01 2:30 pm By Miklos Bolza | Sydney
Please login to bookmark Close

US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au